Engineered NK cells take on tough cancers in first human test

NCT ID NCT07621471

Not yet recruiting Disease control Sponsor: Genovn Therapeutics (Suzhou) Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests a new type of immune cell therapy for people with advanced solid tumors that have not responded to standard treatments. The therapy uses a patient's own natural killer (NK) cells that have been genetically modified to produce IL-15, a protein that helps them survive and fight cancer longer. The study will enroll 12 participants to check safety and find the right dose.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: genetically engineered natural killer (NK) cells that produce IL-15
What this could lead to: If it works, this could point toward a new treatment option for people with hard-to-treat solid tumors that have spread.
What could go wrong: This is a very early, small trial (12 people) focused on safety, not effectiveness. The treatment may not shrink tumors or could cause serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CANCER SOLID TUMORS

Contacts and locations

Locations

Xinqiao Hospital

Chongqing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.